By Xinhua News Agency
The registration for clinical trials on the antiviral drug Remdesivir has been approved, and the first batch of pneumonia patients infected by the novel coronavirus (2019-nCoV) are expected to start taking the drug on Thursday, according to an official conference Wednesday.
This was according to Professor Cao Bin, head of the antiviral drug Remdesivir’s clinical trial program, who spoke at a conference in Wuhan, central China’s Hubei Province on Feb. 5.
The approval is jointly supported by the Ministry of Science and Technology (MOST), the National Health Commission and the National Medical Products Administration.
Remdesivir is a drug developed by Gilead Sciences, an American pharmaceutical company, said Cao Bin, head of the drug’s clinical trial program, at the conference held by the MOST at the Wuhan Jinyintan Hospital, central China’s Hubei Province.
The drug has shown good antiviral activity against SARS and MERS coronavirus in previous cell and animal experiments. Its clinical trials against Ebola infections have been conducted abroad. In related domestic research, it has also shown fairly good antiviral activity against the 2019-nCoV at the cellular level, said Cao.
A total of 761 patients have been enrolled in the trials, which will adopt a randomized, double-blind and placebo-controlled study method.
The trials, led by the China-Japan Friendship Hospital and the Institute of Materia Medica under the Chinese Academy of Medical Sciences (CAMS), will be conducted in several hospitals in Wuhan, including the Wuhan Jinyintan Hospital.
Hopes have been pinned on the drug, but we have to wait for results of its actual effectiveness in the clinical trials, said Wang Chen, vice president of the Chinese Academy of Engineering and president of the CAMS.